Abingdon, Oxon, UK, 15November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines today announces that it has received the necessary regulatory approvals to initiate a Phase I clinical trial to evaluate the safety and tolerability of its vaccine candidate for SARS-CoV-2, the virus which causes COVID-19.
The Phase I trial is a double-blind, randomised and comparator-controlled study of two groups of 13 volunteers at high and low doses. In addition to providing safety and tolerability data, early data on CD8+ T-Cell mediated immune responses as a surrogate of protection against COVID-19 will be provided. The trial will be conducted by Professor Blaise Genton, Principal Investigator, from the Center for Primary Care and Public Health at the University of Lausanne, Switzerland. The first patient is anticipated to receive their first dose of Emergex vaccine candidate at the start of January 2022.
A Phase I clinical trial (NCT04935801), named naNO-DENGUE, testing Emergex’s Dengue vaccine candidate is currently underway in Switzerland with all patients having received two vaccine doses.
Robin Cohen, Chief Commercial Officerat Emergex Vaccines, commented: “OurT Cell priming vaccines mayoffer significant benefits over current COVID-19 vaccines including longer lasting immunity and broader protection against new variants.We are proud to announce the initiation of this trial and look forwardto gathering data to support the development of this important next generationvaccine.”
Professor Blaise Genton, Principal Investigator for the trial from the Center for Primary Care and Public Health (Unisante) at the University of Lausanne, Switzerlandcommented: “Although current COVID-19 vaccines have made significant progress in reducing mortality and morbidity challenges still remain, especially with the development of new variants.Thisexciting new scientific approach to developing a vaccine against SARS-CoV-2 addresses the need to generate a T-Cell response to elicit long termimmunity.We look forward to evaluating the results as when they are available.”